Marinomed Biotech AG
F:MBG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Marinomed Biotech AG
F:MBG
|
AT |
|
Xtacy Therapeutics Corp
OTC:XTCYF
|
CA |
|
C
|
China TMK Battery Systems Inc
OTC:DFEL
|
CN |
|
S
|
Simply Better Brands Corp
XTSX:SBBC
|
CA |
|
A
|
American Transportation Holdings Inc
OTC:ATHI
|
US |
|
B
|
Brother Industries Ltd
OTC:BRTHY
|
JP |
|
G
|
Gigante Salmon AS
F:96M
|
NO |
|
C
|
CVD Equipment Corp
F:0V3
|
US |
|
Q4 Inc
F:I1F
|
CA |
|
Optimus Group Co Ltd
OTC:OPTGF
|
JP |
|
N
|
Nathan's Famous Inc
XMUN:NFA
|
US |
|
N
|
Neovacs SA
F:0LW
|
FR |
|
N
|
Newrange Gold Corp
F:X6C
|
CA |
Wall St Price Targets
MBG Price Targets Summary
Marinomed Biotech AG
According to Wall Street analysts, the average 1-year price target for MBG is 57.61 EUR with a low forecast of 36.35 EUR and a high forecast of 78.62 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is MBG's stock price target?
Price Target
57.61
EUR
According to Wall Street analysts, the average 1-year price target for MBG is 57.61 EUR with a low forecast of 36.35 EUR and a high forecast of 78.62 EUR.
What is the Revenue forecast for Marinomed Biotech AG?
Projected CAGR
81%
Over the last 7 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 4 years is 81%.
What is the Gross Profit forecast for Marinomed Biotech AG?
Projected CAGR
33%
Over the last 7 years, the compound annual growth rate for Gross Profit has been 6%. The projected CAGR for the next 4 years is 33%.
